Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of HRS5091 on Probe Drugs Pharmacokinetics
NCT05273775Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-5091 in Chronic Hepatitis B (CHB), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to last measurable concentration and 1 more. Started Apr 2022; status: completed.
02
Drugs
HRS-5091
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05273775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05273775.